# NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

> **NCT06494514** · NA · RECRUITING · sponsor: **Du Juan** · enrollment: 40 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Cancer

## Interventions

- **DRUG:** nal-IRI+Oxaliplatin+5-FU/LV+PD-1
- **DRUG:** Gemcitabine + albumin-paclitaxel+PD-1

## Key facts

- **NCT ID:** NCT06494514
- **Lead sponsor:** Du Juan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494514, "NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06494514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*